Glycated hemoglobin News and Research

RSS

People with higher blood sugar levels more likely to have memory problems

Even for people who don't have diabetes or high blood sugar, those with higher blood sugar levels are more likely to have memory problems, according to a new study published in the October 23, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

24 Oct 2013

EKF publishes new white paper detailing successful evaluation of POCT HbA1c analyzers

EKF, announces publication of a new white paper detailing the successful external evaluation of its Quo-Test and Quo-Lab glycated hemoglobin analyzers.

From EKF Diagnostics 23 Oct 2013

New NPS MedicineWise case study focuses on type 2 diabetes

The latest NPS MedicineWise case study Type 2 diabetes: tailoring ongoing treatment has been launched in a new dynamic online format. The case study focuses on available treatment options for a 75-year-old male with type 2 diabetes and offers continuing professional development points for GPs, pharmacists and nurses.

22 Oct 2013

DiaRem score predicts diabetes remission after gastric bypass

A new scoring system offers a “scientifically valid” way of predicting the 5-year likelihood for diabetes remission in patients undergoing gastric bypass surgery, say the researchers who developed the score.

20 Sep 2013

Novel DiaRem scoring system can predict diabetes remission after gastric bypass surgery

US Scientists have developed a simple scoring system (DiaRem), based on four readily available preoperative patient characteristics, that can predict which candidates for gastric bypass surgery are likely to achieve diabetes remission within 5 years.

13 Sep 2013

Study assesses relationship between BMI and CV events in hypertensive patients with diabetes

Low BMI is a risk factor for CVD in hypertensive patients with diabetes, according to research presented at the ESC Congress today by Dr Takanori Nagahiro from Japan. The findings provide evidence for an obesity paradox in hypertensive patients with glucose intolerance.

3 Sep 2013

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial presented at the European Society of Cardiology Congress.

2 Sep 2013

Insulin pumps more effective at controlling blood sugar in children with type 1 diabetes

The longest and largest study of the effectiveness of insulin pumps to treat type 1 diabetes in children has shown that the pumps are more effective at controlling blood sugar than insulin injections and cause fewer complications.

20 Aug 2013

Study: Type 2 diabetic patients treated with DPP-4 linagliptin experience reductions in blood glucose levels

Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.

17 Aug 2013

Artificial pancreas for type 1 diabetes patients: an interview with John Pritchard, Cambridge Consultants

Essentially, what an artificial pancreas would be doing is taking the blood glucose results from a continuous monitor and taking the data that the patient puts in about the amount she/he is eating, and then adjusting the amount of insulin being delivered by the pump based on a mathematical formula that would be very personalized to that patient.

25 Jul 2013

BHR to demonstrate EKF Quo-Test HbA1c analyser at Heart UK's conference

EKF, announces today that the Quo-Test, its glycated haemoglobin analyser for near-patient monitoring of diabetes will be on show at Heart UK.

From EKF Diagnostics 2 Jul 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

Weight-loss surgery may improve metabolic risk factors in obese patients: Study

Among mild to moderately obese patients with type 2 diabetes, adding gastric bypass surgery to lifestyle and medical management was associated with a greater likelihood of improved levels of metabolic risk factors such as blood glucose, LDL-cholesterol and systolic blood pressure, according to a study in the June 5 issue of JAMA.

5 Jun 2013

Activ8rlives 2.0 goes live with new self monitoring capabilities for health and wellness

Activ8rlives’ website version 2.0 has now gone live after several months of preparation and testing. Activ8rlives focuses its online self monitoring solutions for health and wellness, which is utilized by families, groups and companies.

3 Jun 2013

MannKind completes AFREZZA Phase 3 clinical study in patients with type 1 diabetes

MannKind Corporation today announced that all follow-up visits have been completed for the patients enrolled in Study 171, a Phase 3 clinical study of AFREZZA (insulin human [rDNA origin]) inhalation powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-generation inhaler. MannKind expects to release data from this study later this summer.

1 Jun 2013

FDA approves Tina-quant HbA1cDx assay for diagnosis of diabetes

Today the U.S. Food and Drug Administration announced that it is allowing marketing of the COBAS INTEGRA 800 Tina-quant HbA1cDx assay (Tina-quant HbA1cDx assay) for the diagnosis of diabetes by health care professionals.

24 May 2013

Newer class of diabetes medications may also improve cardiovascular health, researchers report

A newer class of medications used to control blood sugar levels in type 2 diabetics may also improve cardiovascular health, researchers from The Ohio State University Wexner Medical Center reported in a new meta-analysis presented yesterday at the American Society of Hypertension's Annual Scientific Meeting and Exposition.

17 May 2013

Abbott receives CE Mark for ARCHITECT HbA1c test

Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.

9 May 2013

Organic pollutants increase nephropathy risk in diabetes

Individuals with diabetes may reduce their risk for developing nephropathy if they minimize their exposure to persistent organic pollutants, suggest researchers.

29 Apr 2013